New scan could reveal within days if brain tumor treatment is working

NCT ID NCT02902757

Completed Knowledge-focused Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This pilot study tested whether a type of PET/CT scan (FDG PET/CT) can detect very early changes in glioblastoma tumors after starting chemotherapy. Seven patients with high-grade glioma were scanned shortly after beginning therapy to see if changes in glucose uptake could predict later response. The goal was to find a way to quickly tell if treatment is working, potentially allowing doctors to adjust therapy sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fludeoxyglucose F-18 (FDG)
What this could lead to: If successful, this imaging method could help doctors quickly see if a glioblastoma treatment is working, allowing earlier adjustments.
What could go wrong: This was a very small pilot study with only 7 participants, so results may not apply to all patients. The technique is still experimental and not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.